Overture’s DaVitri Gains CE Mark to Automate IVF Embryo Vitrification

Overture Life’s DaVitri system, an automated in vitro fertilisation (IVF) platform, has received a CE mark in Europe, positioning the Spain-headquartered company to expand commercialisation across Europe and the UK. The benchtop system automates the vitrification of mature oocytes, a technically demanding step in IVF that involves fast-freezing embryos in a glasslike state. By using microfluidics, robotics, and cloud connectivity, DaVitri reduces operator variability and standardises egg thawing and freezing, aiming to improve embryo formation outcomes.

Overture is also conducting a US non-inferiority study comparing DaVitri with manual vitrification, with blastocyst development as the primary endpoint. Rising infertility rates, delayed parenthood, and growing adoption of assisted reproductive technologies (ART) are driving IVF uptake in Europe, with over 1.1 million cycles reported in 2021. Overture plans to integrate artificial intelligence to further enhance embryo selection and optimise IVF success, supported by a €20 million European Investment Bank loan for AI development.

25-11-2025